ArticleOPEN ACCESS

Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial

Blood
DOI: 10.1182/blood.2021012589
25Citations
Citations of this article
32Readers
Mendeley users who have this article in their library.

This article is free to access.

Cite

CITATION STYLE

APA

Garcia-Manero, G., Mufti, G. J., Fenaux, P., Buckstein, R., Santini, V., Díez-Campelo, M., … Komrokji, R. S. (2022, January 27). Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial. Blood. Elsevier B.V. https://doi.org/10.1182/blood.2021012589

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free